The global artificial intelligence (AI) in drug repurposing market size was valued at USD 1.3 billion in 2025 and is projected to reach USD 7.7 billion by 2033, growing at a CAGR of 24.5% from 2026 to 2033. Rising demand for cost-effective drug development, increasing clinical trials in drug repurposing, and growing prevalence of rare and complex diseases are significant factors contributing to market growth.
In addition, growing focus on precision medicine and targeted drug development and improvements in computing power and cloud infrastructure are some other factors fueling market growth. The rising demand for cost-effective drug development strategies substantially drives the AI in drug repurposing market. Traditional drug discovery involves lengthy timelines, often exceeding a decade, and costs frequently exceed USD 2 billion per drug. Drug repurposing offers a strategy to bypass early-stage safety testing by focusing on approved or investigational drugs for new indications. AI accelerates this process by rapidly analyzing extensive biological, chemical, and clinical datasets to identify novel drug-disease associations. This reduces development timelines and costs, offering pharmaceutical companies and healthcare providers an economically viable alternative to de novo drug development. Integrating artificial intelligence into drug repurposing effectively addresses key industry challenges by enhancing productivity while reducing associated risks and investment costs.
AI systems integrate multi-omics data, including genomics, proteomics, and metabolomics, with biomedical literature and real-world patient records to identify subtle and previously unrecognized drug-target interactions. These methods enable the identification of polypharmacology candidates and synergistic drug combinations, overcoming limitations of traditional hypothesis-driven discovery. For instance, in April 2025, Plex Research partnered with Ginkgo Bioworks to use AI-powered analysis on the GDPx2 dataset, a large transcriptomics survey of compound-induced gene expression. This collaboration aims to identify novel disease mechanisms, discover new therapeutic applications, and accelerate drug repurposing, linking findings with experimental data for rigorous validation.
Furthermore, the rising prevalence of rare diseases further propels market growth. For instance, according to the data published by The Lancet Journal in March 2024, around 300 million people live with rare diseases, affecting around 3.5% - 5.9% of the global population. Moreover, around 80% of rare diseases are genetically caused, almost 70% of which are present in childhood. AI facilitates the analysis of limited datasets from rare disease cohorts, enabling the identification of therapeutic candidates from existing drugs and thereby expediting treatment access.
This product will be delivered within 1-3 business days.
In addition, growing focus on precision medicine and targeted drug development and improvements in computing power and cloud infrastructure are some other factors fueling market growth. The rising demand for cost-effective drug development strategies substantially drives the AI in drug repurposing market. Traditional drug discovery involves lengthy timelines, often exceeding a decade, and costs frequently exceed USD 2 billion per drug. Drug repurposing offers a strategy to bypass early-stage safety testing by focusing on approved or investigational drugs for new indications. AI accelerates this process by rapidly analyzing extensive biological, chemical, and clinical datasets to identify novel drug-disease associations. This reduces development timelines and costs, offering pharmaceutical companies and healthcare providers an economically viable alternative to de novo drug development. Integrating artificial intelligence into drug repurposing effectively addresses key industry challenges by enhancing productivity while reducing associated risks and investment costs.
AI systems integrate multi-omics data, including genomics, proteomics, and metabolomics, with biomedical literature and real-world patient records to identify subtle and previously unrecognized drug-target interactions. These methods enable the identification of polypharmacology candidates and synergistic drug combinations, overcoming limitations of traditional hypothesis-driven discovery. For instance, in April 2025, Plex Research partnered with Ginkgo Bioworks to use AI-powered analysis on the GDPx2 dataset, a large transcriptomics survey of compound-induced gene expression. This collaboration aims to identify novel disease mechanisms, discover new therapeutic applications, and accelerate drug repurposing, linking findings with experimental data for rigorous validation.
Furthermore, the rising prevalence of rare diseases further propels market growth. For instance, according to the data published by The Lancet Journal in March 2024, around 300 million people live with rare diseases, affecting around 3.5% - 5.9% of the global population. Moreover, around 80% of rare diseases are genetically caused, almost 70% of which are present in childhood. AI facilitates the analysis of limited datasets from rare disease cohorts, enabling the identification of therapeutic candidates from existing drugs and thereby expediting treatment access.
Global Artificial Intelligence In Drug Repurposing Market Report Segmentation
This report forecasts, revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented global artificial intelligence (AI) in drug repurposing market report based on component, technology, application, end-use, and region.Component Outlook (Revenue, USD Million, 2021-2033)
- Software & Platforms
- Services
Technology Outlook (Revenue, USD Million, 2021-2033)
- Machine Learning/Deep Learning
- Natural Language Processing (NLP)
- Knowledge Graphs & Network-Based AI
- Generative AI & Large Language Models (LLMs)
- Computer Vision
Application Outlook (Revenue, USD Million, 2021-2033)
- Oncology
- Neurology
- Cardiology
- Infectious Diseases
- Rare & Orphan Diseases
- Other Therapeutic Areas
End-use Outlook (Revenue, USD Million, 2021-2033)
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Artificial Intelligence in Drug Repurposing Market Variables, Trends & Scope
Chapter 4. Artificial Intelligence in Drug Repurposing Market: Component Estimates & Trend Analysis
Chapter 5. Artificial Intelligence in Drug Repurposing Market: Technology Estimates & Trend Analysis
Chapter 6. Artificial Intelligence in Drug Repurposing Market: Application Estimates & Trend Analysis
Chapter 7. Artificial Intelligence in Drug Repurposing Market: End Use Estimates & Trend Analysis
Chapter 8. Artificial Intelligence in Drug Repurposing Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- BostonGene Corporation
- BenevolentAI
- Innophore
- Delta4.ai
- BioXcel Therapeutics Inc.
- BullFrog AI Holdings, Inc.
- Graphwise
- Owkin, Inc
- Insilico Medicine
- Healx
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 1.3 Billion |
| Forecasted Market Value ( USD | $ 7.7 Billion |
| Compound Annual Growth Rate | 24.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
